Addressing Counterfeiting and Fraud Concerns in Healthcare

Packaging and Labeling with Blockchain: Opportunities and

Challenges

ANTONIO PESQUEIRA1, MARIA JOSÉ SOUSA1, ANDREIA DE BEM MACHADO2

1ISCTE - University Institute of Lisbon,

Av. das Forças Armadas, 1649-026 Lisbon,

PORTUGAL

2Universidade Federal de Santa Catarina,

Florianopolis,

BRAZIL

Abstract: - Blockchain technology (BT), originally developed to facilitate secure digital monetary transactions,

has recently gained significant traction in various healthcare sectors. Characterized by the exponential growth

of sensitive data, the healthcare sector is poised to witness the emergence of BT. This emergence is primarily

driven by the pressing need to globally expose, protect against threats, ensure confidentiality, and establish

traceability for the plethora of sensitive data continuously generated by the healthcare industry. The healthcare

supply chain focuses on traceability due to the prevalence of counterfeit and recalled drugs. Managing

operational constraints such as temperature, humidity, and air quality within specified parameters is paramount.

The various processes involved in international trade transactions contribute to the creation of numerous

records, each of which is meticulously entered into the systems of the companies involved. Therefore, the

problem set for this study was: What are the challenges and prospects for BT in the healthcare sector? To

answer this question, the following objective was set: describe and examine the challenges and prospects of BT

in the healthcare sector. In addition, a key research objective was to identify specific applications and use cases

that can benefit the most from this technological advancement. In line with the research objective, a systematic

review of all studies BT for traceability, anti-counterfeiting, and fraud detection was conducted from January

2023 to September 2023. Using robust tools such as VosViewer, we used bibliometric metrics from the

renowned medical repository PubMed to construct and visually represent data analysis networks. BT shows

remarkable potential to improve traceability and optimize supply chain management within healthcare

organizations. The study includes a deep analysis of blockchain capabilities, including smart contracts, identity

management, access control, and zero-knowledge proofing.

Key-Words: - Blockchain, Healthcare, Traceability, Supply Chain, Pharmaceuticals, Innovation.

Received: June 25, 2023. Revised: February 13, 2024. Accepted: April 6, 2024. Published: May 9, 2024.

1 Introduction

The pharmaceutical industry and global public

health face several challenges, such as counterfeit

medicines in circulation, which pose an enormous

threat to patient safety but also undermine the

legitimate therapeutic pathway. The current

challenges posed by counterfeit medicines have

been exacerbated by several factors, including the

complexity of supply chains, lack of transparency,

and inefficiencies in security measures. New

solutions must be developed that require more

serialization, traceability, and authenticity control

mechanisms. Protecting the quality, safety, and

efficacy profiles of available medicines is critical to

the quality of care and treatment for millions and is

a vital component of the global healthcare system.

The overall economic cost losses and indirect cost

burden associated with counterfeit drugs, and

fraudulent products are enormous, but then also the

associated risks for patients, including treatment

failure, disease progression, and adverse drug

reactions, [1], [2], [3].

Then, the ability for patients to track and verify

the authenticity of medicines can also be a

challenging task, as system connections and

harmonized supply chain mechanisms in data and

information exchange are still an area for

improvement, especially when the product moves

WSEAS TRANSACTIONS on INFORMATION SCIENCE and APPLICATIONS

DOI: 10.37394/23209.2024.21.24

Antonio Pesqueira, Maria José Sousa,

Andreia De Bem Machado

E-ISSN: 2224-3402

246

Volume 21, 2024

from different healthcare organizations to others

(e.g., from manufacturing companies to pharmacies

or hospitals). However, more advanced

counterfeiters can also introduce counterfeit

products by completely bypassing regulations and

procedures, sometimes due to a lack of preventive

and control measures by governments. In addition,

the increase of e-commerce and online pharmacies

then poses several different challenges due to the

availability of digital channels that might exist

without control or regulation and make more easily

and freely available for counterfeit drugs to reach

consumers directly, [4], [5].

Recently, Blockchain Technology (BT) has

emerged as a promising solution in various

healthcare and pharmaceutical use cases due to its

ability to provide security measures, decentralized

identity management, and traceability of

transactions along with protection, [4], [5], [6].

BT, as a distributed ledger that enables

transactions to be secured and with cryptography as

a key pillar, enables different opportunities in terms

of activating capabilities as a decentralized

distributed ledger. However, BT's capabilities in

terms of decentralization, transparency of

operations, and immutability are also key

components in preventing the circulation and spread

of counterfeit drugs. Recognizing the importance of

today's pharmaceutical supply chain challenges and

bringing some BT considerations to improve the

security and traceability of these supply chains is a

growing need among today's executives, [5], [6], [7]

Overall, the healthcare industry is experiencing

a large and even exponential increase in the volume

and complexity of connected data. Compared to

centralized and still very traditional data

management systems, the likelihood of cyber-

attacks is higher compared to decentralized

solutions where BT provides a more secure platform

through cryptographic security measures. These are

seen as qualities to address the supply chain

challenges faced by the pharmaceutical industry. By

providing a transparent and immutable platform for

transactions, BT offers a method to create a record

of every step in the drug supply chain process from

manufacturing to distribution, effectively preventing

counterfeit drugs, [2], [3], [7].

In the following sections, BT is analyzed in

more detail, highlighting its potential applications in

the pharmaceutical industry and providing a

balanced analysis of its advantages and

disadvantages. The healthcare supply chain

management (SCM) issues related to counterfeiting

and fraud will be key points discussed throughout

the research paper, with the main objective of

assessing how BT can improve supply chain

security and efficiency. Some of the most

highlighted benefits of BT in terms of SCM have

been around its ability to change and also in terms

of preventive mechanisms around tampering and

avoidance of false product and manufacturing

identification information. However, recent research

on BT clearly shows that securely managing

healthcare-related data, which can be extremely

sensitive when it comes to pharmacovigilance or

patient-related data, still requires further assessment

and a better understanding of its confidentiality and

integrity. Some of the available literature

strengthens the supporting arguments that BT can

offer various advantages in terms of overcoming

barriers in the areas of SCM such as serialization,

packaging, and labeling in terms of product

identification, traceability, and many other areas.

BT capabilities around traceability offer several

different advantages in terms of traceability options

and also according to some of the highlighted

literature reviews, [1], [3].

In line with the key concepts described above,

this study examines the impact of technology on the

pharmaceutical sector, with a particular focus on

packaging and labeling practices. In addition, the

paper examines how BT can be used to improve

traceability and security within the supply chain,

combat counterfeiting and fraudulent activities, and

improve medication adherence and patient safety. It

also explores the opportunities created by

blockchain to simplify operations and promote data

sharing among participants in the healthcare

network.

As a result, the purpose of this paper is to foster

a deeper understanding of the role blockchain can

play in healthcare and to catalyze further research

and development in this area of growing interest.

Also, this research paper will examine the

related regulatory concerns, and the ethical and

compliant use of BT in healthcare, but then also

provide considerations in terms of standards and

frameworks to facilitate the integration of BT into

specific areas addressing counterfeiting and fraud

concerns.

The scope of this paper includes a systematic

literature review in terms of the application of BT in

healthcare with a critical analysis of the key benefits

and challenges in terms of BT adoption, but also

with an overview of current BT implementations

within the industry.

Intending to provide key considerations for the

future development of BT in specific SCM areas,

another key supporting objective is to provide

policymakers, industry leaders, and healthcare

WSEAS TRANSACTIONS on INFORMATION SCIENCE and APPLICATIONS

DOI: 10.37394/23209.2024.21.24

Antonio Pesqueira, Maria José Sousa,

Andreia De Bem Machado

E-ISSN: 2224-3402

247

Volume 21, 2024

professionals with insights and perspectives on the

strategic implementation of BT in healthcare.

The research objectives guided a review of

studies on technologies to improve traceability,

combat counterfeiting, and detect fraud between

January 2023 and September 2023. Using tools such

as VosViewer, we analyzed data from the renowned

medical database PubMed to visualize data analysis

networks. Overall, this research will show that BT

can have a significant impact and depends on the

context proposed. Some of the conclusions

highlighted present differences in terms of what was

the applied context, but also accordingly the impact

on the industry.

The opening section paves the way for an in-

depth exploration of the impact of BT on the

pharmaceutical sector. It highlights the issue of

drugs in supply chains as an obstacle that requires

innovative remedies, introduces blockchain as a

plausible solution to this problem, and outlines the

objectives, scope, and importance of the research

paper.

2 Theoretical Background

2.1 Drugs Traceability

The concept of drug traceability involves the

concept of explaining the ability to track and trace

the movement of any pharmaceutical drugs through

the entire supply chain from manufacturing to

distribution to any specific healthcare organization

like hospitals pharmacies or others. Overall, this

process involves documenting and monitoring the

ability of each step the drug takes to ensure the

authenticity, quality, and safety of the designated

product. The drug traceability process is crucial

from the perspective of five key concepts. The first

is related to counterfeit prevention, where tracking

the movement of drugs makes it easier to identify

and prevent the introduction of counterfeit products

into the supply chain, where several of the concerns

associated with counterfeit drugs are risks of

harmful use and, fatal conditions associated with

patients, [2], [7].

Then the ability of recall efficiency if a drug

needs to be recalled due to safety concerns, and

traceability allows for a quick and efficient removal

of the affected product from the market, minimizing

potential harm to patients. The third key area is

related to supply chain security, where traceability

enhances the security of the pharmaceutical supply

chain by providing detailed information on the

movement of medicines, helping to prevent theft,

diversion, and other fraudulent activities, [8], [9],

[10].

The fourth key component is related to

regulatory compliance, where different countries

have regulations that require the traceability of

drugs, most of the time also related to the

serialization of national regulations and procedures.

The last major step is related to transparency and

trust, where traceability contributes to transparency

in the supply chain and builds trust among

consumers, healthcare providers, and regulators

regarding the quality and safety of pharmaceutical

products. To implement drug traceability,

stakeholders in the pharmaceutical supply chain use

a variety of technologies and systems, including

serial numbers, which are unique identifiers for each

drug package and enable individual tracking.

Barcodes and QR codes can be scanned at various

points in the supply chain to track the movement of

medicines. But also, RFID tags, which provide

another way to track drugs without the need for

direct line-of-sight scanning. BT provides a secure,

immutable ledger for recording transactions, making

it ideal for improving the traceability and security of

the drug supply chain, [9], [10], [11].

In the context of SCM, and particularly in the

context of healthcare, the need for robust trust and

transparency requirements for medicines is

fundamental. The drug traceability component

assumes a relevant journey as a critical process to

ensure that all steps are taken to achieve visibility of

the product lifecycle and transportation details.

The overall vigilance is also related to

compliance and product quality control, also in

terms of increasing preventive control mechanisms

in case of a necessary product recall. And here the

use of data analytics and data reporting assumes a

very relevant role in terms of improvement areas

and defining strategies around supply chain

management excellence. Traceability is also a key

component in terms of order and financial control,

but also in terms of inventory management, and

other relevant SCM reporting areas, [12], [13], [14].

The entire pharmaceutical industry involves

complex tasks in terms of SCM, starting from the

distribution of raw materials, through the production

of samples and the final drug substance for clinical

trials, to the packaging, labeling, and distribution

processes. Overall, the entire lifecycle of the process

not only starts from the creation and distribution of

drugs but also covers the final path of patient access

to these drugs. In terms of access, it can go from the

investigational or approved final product through

clinical trials and regulatory assessments to a pre-

marketing or commercialization phase. Where in

WSEAS TRANSACTIONS on INFORMATION SCIENCE and APPLICATIONS

DOI: 10.37394/23209.2024.21.24

Antonio Pesqueira, Maria José Sousa,

Andreia De Bem Machado

E-ISSN: 2224-3402

248

Volume 21, 2024

between all the processes the supply chain

management processes in terms of overall cycles

can involve several different stakeholders. However,

throughout the process some of the major challenges

are related to the lack of data transparency and even

mismatches or inconsistencies as several process

steps are connected, [13], [14], [15].

The literature points in the direction that several

pharmaceutical manufacturers invest different

resources in terms of regulatory functions, but very

few resources are invested in terms of transparency

or data management governance protocols to ensure

transparency and traceability, and sensitive areas

such as side effect tracking, and adverse event

monitoring are ignored along with effective product

traceability. The literature also highlights the

importance of having harmonized and standardized

data protocols in terms of having different

stakeholders involved in the various traceability

processes under the same common understandings

and procedures, [14], [15], [16].

Future improvements aim to integrate all

process steps into a common layer that provides

comprehensive data access at each step and across

networks, reducing the time and effort required to

retrieve information. However, initiating these

advancements and expanding data ownership in

healthcare product traceability remains a daunting

task for many companies. The healthcare

traceability process involves a wide range of

stakeholders, including clinical supply chains,

medical device manufacturers, and support services

such as contract manufacturing organizations and

regulatory agencies. For manufacturers, ensuring

that clinical shipments are tracked and monitored

from production to distribution and linked to

healthcare providers and patients requires rigorous

quality assurance, cold chain, and inventory

management. Real-time access to the full scope of

supply chain processes remains elusive for

regulatory and compliance organizations, making it

difficult to define the product lifecycle on a single

platform and monitor activity in real-time, [16],

[17].

Future areas of improvement may focus on

increasing process efficiency by digitizing manual

or paper-based processes that are currently tracked

across multiple document repositories, leading to

reconciliation difficulties. Various technology

solutions, in particular BT, are being explored to

link these document repositories or digitize their

content for improved accessibility and analysis.

Such technology integration can facilitate better

decision-making among stakeholders and contribute

significantly to the success of supply chain

initiatives, [7], [18].

2.2 Counterfeit Drugs

The proliferation of counterfeit medicines poses a

serious threat to the health and lives of millions of

people who rely on the authenticity and efficacy of

their prescribed medicines. The spread of

counterfeit drugs including biological products

highlights the pressing importance in terms of

having preventive tactics and measures to prevent

several different risks and overall placing the lives

of several different patients in dangerous conditions.

Counterfeit or falsified drugs present several

different devasting effects and outcomes

consequences in terms of having patients who are

not aware of what kind of drugs are accessible and

available, [18], [19], [20].

In terms of the overall SCM, some of the most

important and responsible players are the

manufacturing companies, but also wholesalers,

public health authorities, and retailers. These players

have different responsibilities in terms of

understanding the whole landscape and how

production, transportation, and distribution can

enable effective countermeasures against the spread

of counterfeit drugs. The entire network has

received different attention from academia in terms

of having different procedures, and technologies in

tackling the overall challenges in terms of tracking

the identification and movement of drugs from

production to the final prescription or dispensing

point and having throughout the process

mechanisms for verification, authentication and

validation of identification and traceability areas.

But not only Public health implications are at the

core of the concerns, but also in terms of impact on

the reputation and financial stability of various

companies. But also, the need for different

protective measures that can work across spectrums

of action and areas of intervention, [21], [22].

Some of the major concerns are in terms of

quality standards, where counterfeit drugs don't

have active ingredients and even look like genuine

products, they don't have any therapeutic value. In

several developed drugs, these counterfeit drugs

may be associated with sensitive areas such as

opioids or antibiotics, or even substances that may

have abuse potentials such as morphine or its

analogs. The overall safety and efficacy risks of

counterfeit drugs can range from undisclosed

ingredients to the presence of substances that can

harm the health of a specific patient or large groups

of patients, such as immunosuppressants, or

WSEAS TRANSACTIONS on INFORMATION SCIENCE and APPLICATIONS

DOI: 10.37394/23209.2024.21.24

Antonio Pesqueira, Maria José Sousa,

Andreia De Bem Machado

E-ISSN: 2224-3402

249

Volume 21, 2024

vulnerable groups, such as the elderly, [11], [17],

[23].

2.3 Blockchain

BT’s establishment with Bitcoin in 2009 as a

sophisticated database is careful to the exceptional

detail of the transaction history’s international

picture. As a component of the database, the block’s

continuous evolution designates them as the means

of instantly checking whether an asset is owned.

The blockchains’ public access and worldwide

presence as an infinite number of nodes and lacking

administration make BT valid only when

objectively, there is a confirmation method. Bitcoin

blockchains, the most renowned in terms of

dependability and security, trust complex

mathematics and expenses for their consensus

arrangements of any use, such as Proof of Work

(PoW) and Proof of Stake (PoS) is different,

predominantly due to alternative cinematographic or

arbitrary validator selections, but since the PoW

replaces computational technology use. The fact that

blockchain allows automated contracts whose

processes are based on various trigger circumstances

illustrates the above illustration of the network’s

characteristics as a facet of openness, lawlessness,

and censorship contrasting the network’s grey face.

Nonetheless, reconstruction is complex and time-

consuming compared to current practices based on

trusted intermediaries, such as digital crawler

remuneration, lease follow-up, and upstream

tracking of products, [17], [19], [24].

Blockchain’s decentralized architecture

eliminates the central authority, which is essential in

addressing issues related to centralized power and

ensuring balanced computing resource distribution.

Such architecture ensures transparency, as it allows

protocols to verify past transactions and record

ownership independently, essential in counterfeit

detection, ensuring traceability and serialization

model validation. Again, integrating blockchain in

the packaging and labeling of the healthcare sector

is a new dawn in data exchange, including the

ability to work on one logical record for all versus

separate records and the authenticity and security of

documentation. The cryptographic approach will

enhance counterfeit drug detection and ensure a

framework that backs up data management across

different jurisdictions; hence, it will provide fail-

safe and confidential data that speeds up the

process, increases security levels, and boosts trust

and transparency on the traceability and validation

of medicine. It is a total shift in the paradigm of the

healthcare sector the measures to facilitate the

effectiveness of blockchain in healthcare are

summarized in. The algorithms and models in this

research area have been used to develop smart

contract protocols for healthcare applications, [23],

[24].

Furthermore, the engineering perspective of

anti-tampering mechanisms also involves the

development of anti-tampering mechanisms for drug

packaging that are linked to BT. For example, newly

redesigned packaging that makes it almost

impossible or noticeable to replicate or destroy it,

and sensors that record and transmit any tampering

with the packaging to the blockchain. Although

there is a broad range of connections, BT allows

patients to independently define the identity of their

medicines. It is the ambition of engineering research

in that field to create an easy-to-use interface, and

system-led guides enabling patients to safely and

comfortably access blockchain data. One example is

the serialization of drugs utilizing blockchain; the

business is presently experimenting with the

technology to assign a distinct identifier to each unit

of a drug to trace a product through the supply

chain. Temperature tracking is also being taken

using blockchain-based systems to evaluate and

save temperature-sensitive medicines through the

supply chain, [24], [25], [26].

3 Methodology

This section delves into the chosen research

methodology to validate and address the posed

research questions, focusing on assessing various

models and use cases for BT applications and

processes within the healthcare industry through a

systematic literature review.

A systematic review of the existing literature

was conducted to cover various models and

applications of BT in healthcare thoroughly. This

methodical approach was supposed to fill in

knowledge about the problems and opportunities of

implementing BT in healthcare and demonstrate

recent improvements and expectations according to

this technology’s deployment. This methodology is

focused on the meaningful frame of the review

process itself; the elements of methodological

strength include formulating research questions,

choosing filter criteria of relevant studies, selecting

analysis methods, and effective execution of data

analysis. The primary question was related to

identifying the current applications challenges and

perspectives for BT in fighting fraud and improving

traceability in the healthcare industry. Additionally,

the question was purposed to identify the influences

of current BT applications on healthcare

WSEAS TRANSACTIONS on INFORMATION SCIENCE and APPLICATIONS

DOI: 10.37394/23209.2024.21.24

Antonio Pesqueira, Maria José Sousa,

Andreia De Bem Machado

E-ISSN: 2224-3402

250

Volume 21, 2024

organizations’ antifraud and traceability activities

[8], [11].

To achieve a precisely comprehensive review in

the timeliest manner, an elaborate software tool,

VOS Viewer, was used due to its ability to conduct

complex data analysis. This methodology implied

using co-occurrence analysis, analysis of the

strengths of the association, creation of network

graphs, and exploration of the author-level and

citation-network levels. The latter aspect allowed

for identifying co-authorship relationships through

mutual references and a co-link matrix. By applying

advanced bibliometric methods, the review selected

relevant keywords and points of data, as the

importance of the data analysis process cannot be

understated. These techniques specifically helped in

cross-validating the findings of bibliometric and

network analysis. It should be noted that the

objective was to map and understand complex data

links and structure connections in academic articles

based on the articles indexed in the PubMed

database. This involved understanding co-

occurrence relationships including co-words, co-

citations, and co-link matrices, which gave a fuller

understanding of the topic, [8], [11].

Second, the bibliometric and network analyses

identified the key authors, most important studies,

and existing collaboration patterns, as the

relationship between these variables had not been

analyzed by the author of this paper before. The

systematic review in PubMed provided 169 works

selected based on the year of publication and

research, of which 74 met all validation and quality

assessment criteria and were subject to data

extraction analysis, providing a good selection of

materials for analysis. In turn, these seventy-four

works, selected as the basis for methodological

research, provided the bibliometric indicators for a

qualitative study of the scientific network, the co-

authorship, and co-occurrence maps that gave us the

primary tools for analysis and research hypotheses

outlining.

3.1 Search Terms and Data Selection

In this SLR, the initial phase was focused on the

planning stage, where research questions and

keywords were aligned, especially with

combinations such as "Traceability", "Blockchain

Technology", and "healthcare" or "counterfeit

drugs".

The methodical effort to explore the diverse

applications of BT in the healthcare sector,

particularly in addressing the pressing issues of

counterfeiting and traceability, was meticulously

crafted as a search strategy. This strategy included

many synonyms and related terms to ensure

comprehensive coverage of the topic. The search

terms we used were a) blockchain, to capture the

technological aspect; b) healthcare, to focus on the

industry of interest; c) counterfeit, to address the

specific challenge of fraudulent activity; and d)

traceability, to encapsulate the aspect of tracking

and verification in the supply chain.

To refine the search and ensure the relevance

and quality of the publications, we established a set

of strict inclusion and exclusion criteria. These

criteria were critical in filtering out publications that

did not meet our high standards for academic rigor

and relevance. Specifically, we excluded: 1)

publications that were not peer-reviewed, such as

books, theses, tutorials, keynotes, and similar works,

to maintain a focus on scientifically validated

studies; 2) articles that were not available in

English, to ensure that our analysis was conducted

on readily accessible and generally understandable

literature; and 3) research published before 2010, to

ensure a focus on recent developments and

contemporary perspectives in the field.

The above search terms and exclusion criteria

were systematically applied within the PubMed

database. It used specific search terms tailored to

this database to efficiently sift through the vast

amount of literature and isolate those studies that

were most relevant to the research objectives. The

process of implementing these search terms and

applying the exclusion criteria is detailed in Figure

1, which provides a clear visual representation of

our methodological approach to data collection (see

Figure 1 for further illustration).

The systematic review plan, outlined in the

visual representation, is a well-structured approach

to synthesizing literature relevant to the use of BT to

mitigate counterfeiting and fraud in healthcare

packaging and labeling.

The reviewed methodology begins with setting

rigorous inclusion and exclusion criteria to ensure

the relevancy and academic integrity of the

reviewed literature. The research itself is conducted

on the PubMed digital database, which enables the

coverage of a broad range of research. The

identified literature is closely reviewed and analyzed

on the background of a research question that

concerns the primary issues of counterfeit

deterrence and traceability improvement in the

healthcare industry. The third, the scrutinizing

phase, aims to explore the syntax of the studies in

the review. Using bibliometric tools and literature

coupling, the phase uncovers the complex

connections between the publications.

WSEAS TRANSACTIONS on INFORMATION SCIENCE and APPLICATIONS

DOI: 10.37394/23209.2024.21.24

Antonio Pesqueira, Maria José Sousa,

Andreia De Bem Machado

E-ISSN: 2224-3402

251

Volume 21, 2024

Fig. 1: Overview of the selected methodology steps, database search, and selection criteria

Importantly, the review phase helps identify the

works that correspond to the specific, pre-set

research questions and align the review focus with

the intention, [8], [11].

From the 169 articles initially identified via

PubMed, careful exclusion criteria - excluding non-

peer-reviewed material, non-English publications,

and those published before the year 2000 - resulted

in a distilled list of 74 relevant publications. These

publications underwent keyword-based analysis to

ensure alignment with the research question

regarding the impact of blockchain on anti-

counterfeiting and traceability in healthcare.

This research reflects the significant relevance

of the topic within the academic community, as

evidenced by the volume of recent publications. The

74 validated articles represent a rich corpus for

VosViewer analysis, facilitating co-occurrence and

co-authorship analysis that will undoubtedly

contribute to the understanding of blockchain's role

in healthcare product security. Through a carefully

curated review and analysis process, the study

underscores blockchain's potential to serve as a

foundational technology in the fight against

healthcare counterfeiting and fraud and provides

insights into its growing importance and application

in this critical area (Figure 1).

4 Data Analysis and Discussions

4.1 Sample Data Analysis

In this section, we summarize our findings from the

systematic review and present an in-depth analysis

of the bibliographic data extracted from 169

selected articles. Through our analytical procedures,

we have uncovered a variety of sub-themes within

the designated areas of investigation. The

application of statistical methods has allowed us a

deeper understanding of the results obtained from

the literature review, co-authorship assessments, and

co-occurrence investigations, providing us with

quantifiable data and indicators from the scientific

community network. For the analysis of this

particular subsection, we conducted extensive co-

authorship and co-occurrence assessments using the

74 articles that were initially selected.

An examination of the distribution of these 74

publications from 2010 to September 2023 revealed

that 27 percent were contributed to the year 2023

alone. The following figure is indicative of the

escalating importance of our research questions,

both in the scientific realm and in the global context,

as evidenced by the increase in related publications

generated by the identified keywords (Figure 2).

These findings reveal a clear trend and burgeoning

interest in the interplay between BT and supply

chain management pharmaceutical practices, and the

imperative for continued scholarly discourse and

investigation in this area (Figure 2).

WSEAS TRANSACTIONS on INFORMATION SCIENCE and APPLICATIONS

DOI: 10.37394/23209.2024.21.24

Antonio Pesqueira, Maria José Sousa,

Andreia De Bem Machado

E-ISSN: 2224-3402

252

Volume 21, 2024

Fig. 2: Overview of the digital database publication

years

It systematically applied the full count method

to the entire analysis and applied the same weight to

the same link results for consistency in the co-

authorship analyses.

Forty of the 345 authors in the 74 articles met

the quality and criteria, which included at least two

papers by an author and two citations.

In addition, to determine the strength of the

coauthorship links, the strength of the links between

authors was measured, and for this analysis, the

authors with the highest overall strength were

selected. By using the number of documents and

relationships between authors and co-authors, was

calculated the relatedness between them. Then, 40

authors per unit were examined and a full count

strategy was applied along with a maximum number

of documents per author, resulting in all 40 authors

meeting both the inclusion criteria and the

coauthorship threshold.

To define the data analysis definitions, we

required two documents from each author, i.e., we

combined authors whose connections and

relationships allowed us to understand related graph

maps and clustering.

The intricate network shown in the figure

illustrates a dense and robust landscape of scholarly

collaboration, as evidenced by the myriad of

connecting lines and the abundance of names that

populate the visual.

The network diagram, presumably generated by

bibliometric analysis, could represent the

interconnectedness of researchers and academics

who are actively contributing to the discourse on

BT's role in countering counterfeiting and fraud

within healthcare packaging and labeling (Figure 3).

Each node, represented by an author's name,

suggests a focal point of contribution to the body of

knowledge, while the lines infer collaborative

relationships, perhaps through co-authorship or

citation.

This rich mosaic of scholarly work underscores

the dynamic and extensive nature of research

activities, highlighting a thriving community

dedicated to inquiry and innovation. Regarding the

research nodes clustering, evidenced within the

healthcare domain as well, I believe it is due to

further exploration of the themes or methodologies

concerning blockchain applications. This type of

research is undoubtedly of great importance, as it

provides the necessary knowledge on how BT can

help protect pharmaceuticals from counterfeiting

and unauthorized distribution. In addition, there is a

tendency for increased collaboration, which is also

both evident and predictable.

The pattern shows great urgency and

importance in creating strong and reliable strategies

to verify the authenticity and traceability of medical

products. Collaboration is necessary as the

challenges of counterfeit medicine put patients' lives

and healthcare systems in jeopardy. The trend is a

strong indication of the shared commitment to

integration projects using flexible and advanced

technologies that not only ensure consumer

protection but also increase the industry’s ability to

defend itself from counterfeits.

The following network diagram is more than

just a cluster of names and connections; it is a

dynamic representation of the scientific

community's response to the challenge of counterfeit

pharmaceuticals.

It symbolizes the collaborative spirit that is

essential to innovate and develop new standards and

governance models for artificial intelligence in

pharmaceuticals, ensuring that patients receive safe,

authentic medications (Figure 3).

Fig. 3: Network visualization for all 40 authors of

the co-authorship analysis

All analyzed papers that were relevant to both

topics of healthcare products traceability and anti-

counterfeiting presented this cluster of authors that

presented high levels of correlations and linkage

WSEAS TRANSACTIONS on INFORMATION SCIENCE and APPLICATIONS

DOI: 10.37394/23209.2024.21.24

Antonio Pesqueira, Maria José Sousa,

Andreia De Bem Machado

E-ISSN: 2224-3402

253

Volume 21, 2024

between all of them, in terms of the presented

research work and relevant from all 74 analyzed

papers.

For our study, we also used fractionally

counting as an analytical technique to calculate co-

occurrence. It refers to the fact that author weights

are fractionalized so that, if they co-authored a

document, their link weights will be fractionalized

too. 30 out of 285 keywords matched the threshold,

meaning that they were found at least three times.

VosViewer clustering was used to cluster

publications within our 285-citation network. Then

the co-occurrence analysis measures how many

documents, search terms, and keywords are related

between presented items and selections based on

relationships between items and selections.

To determine whether all authorship links

receive the same degree of weight, the co-

occurrences of all terms and keywords were

accounted for in whole numbers instead of

fractionally.

In the following graphs (Figure 4 and Figure 5),

it’s presented the strongest co-occurrence

relationships between terms, which is primarily seen

as relatedness in the context of occurrence

relationships, such as when the number of linked

items is calculated from the number of documents.

Having a large term means that it has appeared

in numerous publications, whereas the distance

between two terms indicates the degree to which

they are related. So, the graphs would display the

strongest relationships between the terms after

comparing the numbers of publications for each

term in addition, the graphs should be understood

because all the colors signify groups of terms that

are comparatively close in relationship.

As a result, curved lines are used in the

visualization to identify the strongest relationships

(Figure 4).

The network map vividly depicts blockchain as

the nucleus of a diverse constellation of terms,

reflecting its multidisciplinary impact and the

breadth of its applications. The map's color-coded

pathways suggest blockchain's interconnectedness

with various sectors, particularly in healthcare,

where it intersects with electronic health records,

privacy, and telemedicine.

In the red cluster, terms such as 'counterfeit

drugs', 'supply chain', and 'IoT' converge around

'blockchain', highlighting its central role in

improving traceability and combating fraud. The

analysis seems to be compatible with the innovative

ways to protect pharmaceuticals from counterfeiting

considering that the terms "smart contract" and

"proof of concept study" are closely related to the

concept of "blockchain." Moreover, the definition of

"IoT," or Internet of Things, may indicate the

possibility of developing a technological alliance

where blockchain would be an eager component of a

secured ecosystem of personal medical devices and

services. Consequently, the analysis facilitates the

intensive development of new ways to improve

security and performance in the delivery and

monitoring of healthcare products.

Second, the blue cluster, which consists of

‘telemedicine’ and ‘smart contracts,’ highlights a

new technological trend in the delivery of medical

services; it can be presumed in light of the COVID-

19 pandemic that this trend has become more

popular. Thus, BT can substantially enhance the

provision of patient care and management of

pertinent health data, enabling those data to be

processed free of any central intermediaries and

allowing for the provision of medical care at a

distance. Third, the green cluster contains the most

critical abilities: data ‘privacy’, ‘algorithms,’ and

‘computer security.’

The fact that blockchain is linked to ‘electronic

health records’ and ‘health information exchange’ in

this cluster reemphasizes the importance of this

technology to the safeguarding of health data

confidentiality and integrity. In this cluster,

blockchain’s use is depicted as a strong barrier to

the existing health data protection and privacy

issues, particularly regarding ensuring that personal

health information is kept secure and private.

Nevertheless, such information is still accessible in

a regulated, transparent way. The general conclusion

is then that blockchain’s corner is technology,

healthcare, and data security. Its central position in

the network map underscores its fundamental role in

addressing the key concerns of authenticity, privacy,

and efficient data management in the healthcare

sector. The map underscores the need for continued

research and development in this area to fully

leverage blockchain's capabilities in creating a safer,

more transparent healthcare system (Figure 4).

The keywords of blockchain (53 occurrences

with a total strength link of 149), electronic health

records (29 occurrences with a total strength link of

118), and privacy (10 occurrences with a total

strength link of 47) illustrate the most relevant co-

occurrences between terms in particular terms

relatedness, occurrence relationships, and associated

numbers of documents.

Each term was measured by the number of

occurrences, and its distance from another term

represents the degree of relatedness between them.

A large number of publications indicates a stronger

WSEAS TRANSACTIONS on INFORMATION SCIENCE and APPLICATIONS

DOI: 10.37394/23209.2024.21.24

Antonio Pesqueira, Maria José Sousa,

Andreia De Bem Machado

E-ISSN: 2224-3402

254

Volume 21, 2024

link between terms, so relatedness becomes more

dependent on co-occurrences.

Fig. 4: Network visualization for all 30 selected

keywords with 4 cluster parts of the co-occurrence

analysis

According to the co-occurrence map creation

based on text data, we selected all fields with the

terms extracted from the titles and abstract fields

from all 74 publications and ignored structured

abstract labels or copyright statements from the

publication's published data. Figure 5 and Figure 6

illustrate the distribution of publications by binary

counting which means that only the presence in a

document matters and instead of counting all

occurrences of a term in a document.

The graphical depiction showcases blockchain's

extensive reach and its interconnectedness with

various domains, emphasizing its multifaceted

implications for the healthcare sector. In the

visualization, blockchain sits at the confluence of

several critical themes, each represented by a

distinct color and demonstrating the technology's

broad spectrum of influence.

The blue cluster emphasizes "patient,"

"privacy," and "data," highlighting the role of

blockchain in handling patient information securely

and confidentially.

Therefore, blockchain has the potential to

revolutionize how patient data is handled, providing

a safer and more private environment for healthcare

systems. The inherent characteristics of blockchain

– decentralization, encryption, and immutability –

ensure that patient data is stored and accessed in a

way that maintains confidentiality while still

meeting the needs of healthcare providers who

require access to identifiable patient records to

perform their duties effectively.

The green cluster represents 'transparency,'

'supply chain,' and 'smart contracts,' indicating the

use of smart contracts to improve transparency in

the healthcare supply chain.

Thus, blockchain can be a new promising way

to enhance the efficiency of various operations from

drug tracking to the confirmation of drug

authenticity. Smart contracts can be used to

automate and secure transactions and agreements at

all stages of the supply chain. Every party involved

will have no other option but to comply with

predetermined contractual conditions and rules.

Finally, such an initiative could decrease the

possibility of counterfeit products penetrating the

market, making quality control and management of

medical supplies more transparent and effective. In

other words, the described accident proves that

blockchain contributes to the transparency of the

pharmaceutical supply chain and can lead to a

revolution in the process of how drugs are tracked

back to the manufacturer or patient, thus increasing

the level of products’ authenticity and reducing the

possibility of counterfeit medicines to reach the

market. The red sector including ‘technology’,

‘research’, and ‘IoT’ also supports the advanced

synergy of blockchain, and several technologies and

this issue can be utilized to support the constant

research needed to utilize these tools for creating

high-quality healthcare solutions.

At the heart of the diagram (Figure 5),

'blockchain' forms the nucleus that binds these

aspects together, signifying its role as a foundational

technology capable of addressing the myriad

challenges presented by the modern healthcare

landscape.

Fig. 5: Network visualization for the most relevant

keywords part of the co-occurrence analysis

The chosen threshold in terms of analysis was a

minimum number of 8 occurrences of a term where

out of 2107 from all 74 publications, only 32 met

the threshold.

WSEAS TRANSACTIONS on INFORMATION SCIENCE and APPLICATIONS

DOI: 10.37394/23209.2024.21.24

Antonio Pesqueira, Maria José Sousa,

Andreia De Bem Machado

E-ISSN: 2224-3402

255

Volume 21, 2024

However, the full counting method was also

applied in terms of better understanding the full

range of the co-occurrence maps based on the title

and abstract textual information from the 74 papers.

We, therefore, selected from the 2107 terms, the

ones that presented the highest levels of the

relevance score and occurrences that were valid to

our scope of work and analysis (Figure 6).

The visualization presented offers a complex

network of terms related to the healthcare sector,

with a pronounced emphasis on the integration of

BT. Central to the network are nodes such as

'platform', 'medicine', 'product', and 'architecture',

which are intricately linked to 'blockchain',

highlighting its central role in the digital

transformation of healthcare.

The 'platform' node, which is connected to

'COVID', 'security', and 'scalability', suggests a

focus on using blockchain for secure, scalable

solutions amid global health challenges. The

closeness of “architecture” to “medicine”, and

“supply chain” shows that blockchain might help

with a more organized and transparent

pharmaceutical supply chain, fighting counterfeit

drugs.

The connection of the red words or “medicine”

and “clinical trials” to blockchain unveils how

medical research can be amended and improved in

regard to management, storage, and execution

through increased data transparency and

authenticity. It is possible to suppose that it will

deliver a tamper-proof immutable ledger more

trustworthy and permanent than those on the current

technologies. Moreover, it will be both a secure and

transparent way to record, store, and spread data

which means any change will be obvious and

transparent as well. With these aspects in mind, it is

clear that blockchain can enable easier purview of

clinical results which mitigates industrial risk of

tampering or malicious reports; thus, it can frame a

standard of quality that must be satisfied.

Additionally, these words even suggest significant

alterations in how medical studies will be

conducted, emphasizing real ones. The system

cluster combines blockchain and the words “medical

record” and “data security”. Most likely, it indicates

a unique way to protect health data vital for medical

compliance. The bright lines running through these

words show that it is a multifunctional device with

transparent results on multiple industry

undertakings, from systematization of data-to-data

security and clinical trials, to supply chain integrity.

This network map serves as a graphical

abstraction for discussions about how blockchain

can be used to address pressing issues in the

healthcare industry, including but not limited to

securing medical records, improving drug

traceability, and streamlining clinical operations.

The visual is a testament to blockchain's ability to

connect various components of healthcare into a

cohesive, secure, and efficient system (Figure 6).

Fig. 6: Levels of relevance and occurrences of all

key terms at the highest level

It was found that, based on our search terms that

included BT applications in healthcare, medication

traceability, and counterfeit prevention, the majority

of research relates to consent protocols, routing

schemes, authentication processes, and identity

systems, among many other topics described in the

above figures and analyses.

Overall, this research, compiled with the

systematic literature review conclusions presented

in Table 1, provided cross-validation of our

systematic literature review conclusions and co-

occurrences and coauthorship analysis presented in

Table 1.

The table provided is a compendium of research

that underscores the pivotal role of BT in enhancing

various aspects of the pharmaceutical industry.

A key part of the table’s information is the

implementation of blockchain to improve the

traceability and security of pharmaceutical supply

chains. This aspect is paramount for addressing the

problem of counterfeit drug distribution, which

remains widespread. As underlined by the identified

study, BT has the power to “adopt distributive

ledger technology to improve drug visibility and

related security”. For example, the Med Secure

System applies blockchain to trace counterfeit

medicine. In this way, it enhances the visibility of

the chain by ensuring that all processes can be

tracked and recognized. Thus, transparency and

process accountability are significantly improved in

such a case. Each study collectively reinforces the

transformative potential of BT as a bulwark against

the challenges posed by counterfeit pharmaceuticals,

WSEAS TRANSACTIONS on INFORMATION SCIENCE and APPLICATIONS

DOI: 10.37394/23209.2024.21.24

Antonio Pesqueira, Maria José Sousa,

Andreia De Bem Machado

E-ISSN: 2224-3402

256

Volume 21, 2024

heralding a new era of secure, transparent, and

reliable healthcare delivery systems.

Table 1. Methodologies and overview of selection to

appropriate publications

Key Concept

Ref.

Connection

Enhancing

Traceability

and Security

[1], [3],

[21],

[27],

[28]

Blockchain technology improves

traceability, visibility, and security in

pharmaceutical supply chains,

preventing counterfeit drugs.

Chain

DrugTrac

Framework

[4], [22],

[28],

[29],

[30]

A blockchain-based framework for drug

traceability and counterfeit detection,

demonstrating effectiveness through a

prototype.

Med Secure

System

[5], [6],

[21],

[30],

[31]

Blockchain-based system for tracking

and tracing counterfeit medicines in the

supply chain.

Mitigating

Counterfeit

Medications

[5], [6],

[10],

[30],

[31],

[32]

Blockchain-based drug traceability

improves pharmaceutical supply chain

transparency and accountability.

Improving

Data Integrity

[1], [9],

[20],

[32],

[33]

Blockchain technology reduces the

circulation of counterfeit drugs by

enhancing data integrity and traceability.

Smart

Contracts for

Drug

Traceability

[5], [10],

[13],

[17],

[34],

[35]

Blockchain approach using smart

contracts enhances drug traceability in

healthcare supply chains.

Decentralized

Health

Infrastructure

[9], [10],

[36],

[37]

Blockchain and smart contracts enhance

product traceability in healthcare,

reducing counterfeit drug risks.

Identifying

Counterfeit

Drugs

[1], [3],

[13],

[28],

[32],

[33]

Blockchain technology traces and

identifies counterfeit drugs in the drug

supply chain.

SUPPLYDEC

K for Supply

Chain

Management

[6], [13],

[14],

[32],

[33],

[34]

Blockchain technology ensures

transparency and security in

pharmaceutical supply chains with

SUPPLYDECK.

Verifying

COVID-19

Vaccine

Provenance

[4], [13],

[14],

[28],

[35]

Blockchain enables patients to verify

COVID-19 vaccine quality, reducing

counterfeits in the pharmaceutical

supply chain.

Securing

Pharmaceutica

l Supply Chain

[9], [10],

[15],

[19],

[36]

Blockchain technology secures

pharmaceutical supply chains by

reducing counterfeiting and manual

operations.

MedBust for

Supply Chain

Revolution

[3], [4],

[20],

[19],

[37]

Blockchain revolutionizes the

pharmaceutical supply chain by

improving efficiency and reducing

counterfeit drugs.

Combating

Counterfeit

Drugs in India

[5], [6],

[9], [24],

[38]

India implements BT to combat

counterfeit drugs in the pharmaceutical

industry.

Ineffective

Traditional

Traceability

Methods

[9], [14],

[16]

Blockchain and IoT ensure safe and

sustainable supply chain operations

against counterfeiting.

Blockchain for

Drug Supply

Chain

Transparency

[10],

[15],

[16]

Blockchain improves drug supply chain

transparency, security, and traceability.

Good

Distribution

Practice Model

[9], [14],

[15],

[24],

Blockchain enhances transparency,

security, and reliability in drug

distribution.

Key Concept

Ref.

Connection

[38]

End-to-End

Traceability

Improvement

[13],

[14],

[15]

Blockchain technology improves

traceability and resilience in the

pharmaceutical supply chain.

Transparency

in Supply

Chains

[13],

[14],

[22]

Blockchain guarantees transparency in

supply chains, particularly in

pharmaceuticals.

Blockchain-

based

Traceability

Meta Model

[13],

[14],

[21]

A meta-model for blockchain-based

supply chain traceability, connecting

actors and events.

It’s possible to infer based on the above table

and the 14 presented publications that 4 studies

represent Finished Goods Traceability, 3 are

representative of Counterfeiting and Finished Goods

Traceability simultaneously, and supply chain and

anti-counterfeiting individually. From the above

representation of the table, we have one study

related to the tracking of medical information and

data.

These 14 publications explain a variety of

proposed solutions and we can conclude that the

application of BT technology is being examined to

improve several different projects, and over the last

few years, the implementation of BC-based

initiatives has been evolving in a variety of ways.

From the reviewed articles, it is evident that

healthcare companies are more responsible than

ever before to automate anti-counterfeiting

processes, traceability processes for drugs, and data

governance and analytics standards to assist in the

decision-making process. Furthermore, through our

research investigations, we can also understand the

importance of BT in providing healthcare

organizations with the ability to manage different

product lifecycles and provide packaging and

labeling solutions to meet public health emergencies

across various cultures.

Additionally, the systematic literature review

model revealed that different BT benefits could be

divided into patient-related benefits, such as

products and data security, personalized healthcare,

patient-reported health data, and monitoring

patients' health states.

Different organizational-related benefits were

also mentioned, including healthcare information

exchange, pharmaceutical supply chains, and

finished goods traceability management. We also

determined that some general threats are associated

with BTs, such as installation and transaction costs,

interoperability issues, and lack of technical skills

on the part of organizational teams, however, we

also perceived social threats, such as social

acceptance and regulation issues slowing down

processing.

WSEAS TRANSACTIONS on INFORMATION SCIENCE and APPLICATIONS

DOI: 10.37394/23209.2024.21.24

Antonio Pesqueira, Maria José Sousa,

Andreia De Bem Machado

E-ISSN: 2224-3402

257

Volume 21, 2024

As a result of the systematic literature review,

we also learned that several healthcare organizations

are partnering with technology companies to

develop a new concept of counterfeit prevention that

combines technology and processes to control

physical materials protection and the way data is

stored on back-end BT platforms that can be

authenticated.

A falsified medicine directive requires that all

prescription medicines are equipped with an anti-

tamper device, which prevents the manipulation of

the medicine. Then, it goes one step further by

serializing the medicine. Among the selected 14

final papers where deeper analysis was conducted,

different conclusions were presented concerning

patient safety, brand protection, or regulations that

drew a need for anti-counterfeit packaging in the

form of temper evidence solutions.

Pharmacovigilance is one of these areas that is

unique since a falsified product is usually detected

only through the package itself, which is designed to

alert the patient.

4.2 Discussions

In the realm of healthcare, the convergence of BT,

counterfeiting, and fraud concerns, particularly in

the context of packaging and labeling, presents a

multifaceted and evolving landscape. This

systematic literature review synthesizes findings

from various academic sources to provide a

comprehensive understanding of this intersection.

BT emerges as a pivotal innovation in healthcare,

offering substantial benefits in enhancing

transparency, security, and efficiency. There are

various healthcare applications of BT, ranging from

safeguarding the identities of patients and providers

to traceability of pharmaceutical and medical device

distribution and even public and open geolocated

data. Possibilities exist for device and patient source

tracking, while clinical trials, pharmaceutical

experiments, and health insurance also seem to take

BT advantages. Nevertheless, the aforementioned

scalability, security, and interoperability difficulties

pose significant barriers to BT’s extensive

implementation in the healthcare industry.

In healthcare packaging and labeling,

counterfeiters are becoming more sophisticated,

complicating the detection and prevention of

counterfeited products. There is an urgent need for

more effective procedures to combat counterfeiting,

given the increasing level of sophistication and the

complexities in establishing a sustainable

monitoring process to track and authenticate

products. Healthcare fraud is prevalent at the global

level and is characterized by multifaceted risks

brought about by fast-evolving fraud patterns and

the compliance of data privacy. Despite the strides

made, there are significant gaps in research,

primarily the integration of BT in existing

healthcare systems to address scalability and

interoperability challenges. More sophisticated

technologies in the detection of counterfeit products

and innovative strategies in fraud prevention,

especially emerging technologies and evolving

frauds, are necessary.

The dynamic field of security, transparency, and

efficiency improvement due to the convergence of

BT, counterfeiting, and fraud in healthcare

packaging and labeling is extremely opportunity-

rich and promising. High-priority areas for research

and further development efforts include the

challenge of technology integration, counterfeit

detection, and fraud prevention. Future research

must proactively look for new solutions and serve as

the basis to develop a theoretical framework to

enable the creation of healthcare systems that are

more secure and efficient. Many of the core BT’s

properties, such as decentralization, transparency,

and prevention of data tampering, are both relevant

and entirely beneficial for any attempts to battle

counterfeiting and fraud in healthcare. Indeed,

blockchain technology can be beneficial for all

organizations, be it a large hospital or a small

pharmaceutical company. In the latter, it provides

logs for transactions that are clear and safe, which

significantly assists in patients’ data protection and

guarantees drug authenticity. Blockchain’s potential

in terms of enhancing healthcare’s safety,

efficiency, and reliability is simply enormous.

However, some of the immediate challenges, such

as complexity of implementation, technical

expertise requirements, and scalability concerns,

remain to be addressed. Once these concerns are

addressed, blockchain technology has unparalleled

potential to revolutionize patient safety and trust

enhancement, fraud and counterfeiting

minimization, care quality improvement, and

reduction of fake drugs. Thus, a reduction in

counterfeiting and fraud will primarily increase the

patient’s safety and confidence.

This inspires trust in the treatment and health

plans, meaning the system must be closely

monitored and patient education must be improved.

Also, regulatory compliance is aided by

blockchain in meeting healthcare industry

regulations through legal standards, audit trails, and

reporting requirements. Simplified compliance

processes and transparent and accessible records for

audits present opportunities, while keeping up with

evolving regulations remains a challenge.

WSEAS TRANSACTIONS on INFORMATION SCIENCE and APPLICATIONS

DOI: 10.37394/23209.2024.21.24

Antonio Pesqueira, Maria José Sousa,

Andreia De Bem Machado

E-ISSN: 2224-3402

258

Volume 21, 2024

Finally, BT adoption is critical to realizing the

benefits of blockchain in healthcare. It drives

innovation, user adoption, and the development of

technology infrastructure. Staying ahead and

gaining an advantage in a competitive environment

encourages innovation, but resistance to change,

ensuring adequate training, and supporting the

adoption of new technologies are significant

challenges (Table 2).

Table 2. Summary overview of main use cases, benefits, and applications

Key Terms

Relations

Key Concepts

Opportunities

Challenges

Blockchain

Enables secure,

transparent, and

immutable

transactions

Decentralization,

Transparency,

Immutability

Enhanced security and traceability in the

supply chain, Improved data integrity,

Regulatory compliance

Implementation cost, technical

expertise required, Scalability

concerns

Counterfeiti

Addressed through

blockchain's

traceability and

verification

capabilities

Authentication,

Verification, Traceability

Reduction in counterfeit products,

Enhanced patient safety, Trust in

pharmaceuticals

Difficulty in complete eradication

of counterfeit products,

Dependence on technology

adoption

Fraud

Concerns

Mitigated by

blockchain's

immutable and

transparent record-

keeping

Data Integrity, Security,

Auditability

Reduced fraud and errors, Improved

regulatory reporting, Enhanced patient

trust

Complexity in integrating with

existing systems, Ensuring user

privacy and data protection

Healthcare

Packaging

Utilizes blockchain

for tracking and

verifying authenticity

Supply Chain

Management, Product

Lifecycle Tracking,

Quality Assurance

Real-time tracking of products,

Assurance of drug authenticity, Efficient

inventory management

Integration with existing supply

chain systems, Ensuring

widespread adoption across

suppliers

Labeling

Benefits from

blockchain's data

management for

accurate information

display

Information Accuracy,

Regulatory Compliance,

Consumer Information

Accurate and tamper-proof product

information, Compliance with labeling

regulations, Informed consumer choice

Aligning BT with labeling

standards, Training for proper data

entry and use

Healthcare

Organization

Different scales of

organizations adopt

blockchain for varied

purposes

Large Hospitals, Medium

Clinics, Small Pharmacies

Tailored blockchain solutions for

different organizational needs,

Competitive advantage

Varying resource availability and

technical capacity across

organizations

Interoperabi

lity

Blockchain facilitates

data exchange among

diverse healthcare

systems

Data Exchange, System

Integration, Collaborative

Healthcare

Seamless patient data sharing, Enhanced

collaboration among providers, Unified

patient records

Achieving interoperability among

diverse healthcare systems, Data

standardization

Patient

Safety

Directly impacted by

reducing

counterfeiting and

fraud

Drug Authenticity,

Medical Record Accuracy,

Treatment Efficacy

Increased confidence in treatment,

Reduced medication errors, Improved

health outcomes

Continuous monitoring for system

effectiveness, Educating patients

and providers about technology

Regulatory

Compliance

Blockchain aids in

meeting healthcare

industry regulations

Legal Standards, Audit

Trails, Reporting

Requirements

Simplified compliance processes,

Transparent and accessible records for

audits, Reduced legal risks

Keeping up with evolving

regulations, Balancing innovation

with regulatory constraints

Technology

Adoption

Essential for realizing

the benefits of

blockchain in

healthcare

Innovation, User

Acceptance,

Technological

Infrastructure

Staying ahead in technological

advancements, gaining a competitive

edge, Encouraging innovation

Resistance to change, Ensuring

adequate training and support, Cost

of new technology adoption

WSEAS TRANSACTIONS on INFORMATION SCIENCE and APPLICATIONS

DOI: 10.37394/23209.2024.21.24

Antonio Pesqueira, Maria José Sousa,

Andreia De Bem Machado

E-ISSN: 2224-3402

259

Volume 21, 2024

5 Discussions

5.1 Recommendations and Limitations

In contemplation of the transformative potential BT

harbors for the healthcare sector, particularly in

mitigating the challenges associated with packaging

and labeling to thwart counterfeiting and fraud, it is

imperative to consider future recommendations that

could pave the way for its effective implementation.

Enhanced scalability of blockchain solutions must

be prioritized to manage burgeoning data volumes

in healthcare systems without impeding

performance. The establishment of universal

interoperability standards is essential for facilitating

efficient data exchange between disparate healthcare

systems. Collaborative engagement with regulatory

bodies will aid in the development of standards and

frameworks that align with blockchain's capabilities,

thereby ensuring compliance and fostering trust.

Moreover, the investment in technical training and

education to address the skills gap will ensure that

healthcare professionals are equipped to navigate

and maintain blockchain solutions.

Placing users at the heart of blockchain application

design is critical, focusing on enhancing usability to

boost adoption among healthcare providers and

patients alike. As blockchain becomes more

integrated into healthcare data management,

advancing strong security protocols is paramount to

safeguard sensitive patient information from new

cyber threats. The healthcare sector stands to gain

from conducting pilot programs and sharing detailed

case studies, which would shed light on the tangible

challenges and benefits of using blockchain in

medical settings. This approach would offer

valuable insights and serve as a guide for future

initiatives.

The complexity of BT in terms of the

technology itself is undoubtedly a challenge to its

wider application in the healthcare sector because

the systems that already function need to

incorporate the blockchain, which becomes time and

capital-consuming. In this regard, data security may

require navigating multiple regulatory policies,

which may be especially challenging for systems

users that include individuals from different

jurisdictions. Lastly, the way various stakeholders

behave and have historical experience is hardly

predictable. Healthcare providers rarely adopt new

tools as they are used to a habit that complicates any

change implementation.

To effectively address these challenges, the

healthcare industry must adopt a comprehensive

strategy. It involves not only simplifying the use of

new technologies for integration but also helping to

adapt them to existing systems, solve any issues

with existing policies and laws, and develop a

culture that is open-minded about innovation.

Wrestling with these problems will allow the

healthcare industry to leverage the full potential of

the blockchain and create safer, more streamlined,

and transparent systems of healthcare service

delivery. It is time to go beyond the theoretical

discussions in academic articles and present an

initiative based on real-world pilot studies and case

studies. The approach in this discussion article will

provide a practical roadmap for the next systematic

research and development, offering a practical

aspect of the use of technology in the real healthcare

setting and its potential.

5.2 Conclusion

BT revolutionizes the healthcare sector by offering

vast improvements in the administration of

pharmaceutical supply chains. While counterfeit

drugs and fraudulent activities such as repackaging

and rebranding are substantial threats across various

fields, blockchain exhibits diverse benefits, such as

better traceability, security, and transparency of

transactions. These aspects play significant roles in

enabling patient-provider trust and ensuring safe

products. Designing supply chain systems based on

blockchain decentralization creates secure, robust

records that cannot be manipulated. It enhances the

integrity of healthcare and supply chains, delivery of

quality services, data integrity, and regulatory

compliance, leading to reduced counterfeit products

and improved patient safety. Besides, product

packaging and labeling can be trackable in real-time

using this technology, ensuring that only authentic,

safe, and effective pharmaceuticals reach patients.

Nevertheless, blockchain has several barriers. This

includes technical complexity and high costs, the

need to integrate blockchain-based systems with

existing technologies, and the importance of

database safety and privacy protection and ethical

data management. Implementation of new systems

is hampered by the inertia of some employees and

industries that are used to old, but most importantly,

labor-intensive methods. Sustainability concerns

demand energy-efficiency mechanisms in

blockchain systems due to high energy

consumption, such as in the Proof of Work model.

As a result, no blockchain system can remain

effective without constant monitoring and updating.

The healthcare sector could benefit from investing

in detergent and more user-friendly designs to

secure health data. Pilot programs and case studies

provide insights. Aggressive global investments in

the healthcare supply chain system are likely to have

WSEAS TRANSACTIONS on INFORMATION SCIENCE and APPLICATIONS

DOI: 10.37394/23209.2024.21.24

Antonio Pesqueira, Maria José Sousa,

Andreia De Bem Machado

E-ISSN: 2224-3402

260

Volume 21, 2024

transformative effects and shift the existing

tendencies to the new creation of medical product

administration and delivery.

Furthermore, extensive pilot studies and real-life

trials validating blockchain applications in various

health settings are critical for capturing their

practical implications and facilitating wider

adoption.

References:

[1] Chari, A., Niedenzu, D., Despeisse, M.,

Machado, C. G., Azevedo, J. D., Boavida-

Dias, R., & Johansson, B. (2022). Dynamic

capabilities for circular manufacturing supply

chains—Exploring the role of Industry 4.0

and resilience. Business Strategy and the

Environment, 31(5), 250-2500.

[2] Jung, D. H. (2022). Enhancing Competitive

Capabilities of Healthcare SCM through the

Blockchain: Big Data Business Model’s

Viewpoint. Sustainability, 14(8), 10-4815.

[3] Banu, A., Annette, R., & Chandran, S. (2023).

A Framework for Securing Health

Information Using Blockchain in Cloud

Hosted Cyber Physical Systems. arXiv

preprint arXiv:2306,10-17084.

[4] Kant, N., & Anjali, K. (2021). Blockchain

Technology: A Strategic Resource. In

Blockchain for Healthcare Systems. CRC

Press. 13, 11-174.

[5] Kshetri, N. (2018). 1 Blockchain’s roles in

meeting key supply chain management

objectives. International Journal of

Information Management, 39, 80-89.

[6] Miyachi, K., & Mackey, T. K. (2021).

hOCBS: A privacy-preserving blockchain

framework for healthcare data leveraging an

on-chain and off-chain system design.

Information Processing & Management,

58(3), 10-17.

[7] Aloini, D., Benevento, E., Stefanini, A., &

Zerbino, P. (2023). Transforming healthcare

ecosystems through blockchain: Opportunities

and capabilities for business process

innovation. Technovation, 119, 102557.

[8] Ebrahimi, S., & Bridgelall, R. (2021). A fuzzy

Delphi analytic hierarchy model to rank

factors influencing public transit mode choice:

A case study. Research in Transportation

Business & Management, 39, 100496.

[9] Raman, R., & Pramod, D. (2017). A strategic

approach using governance, risk and

compliance model to deal with online

counterfeit market. Journal of theoretical and

applied electronic commerce research, 12(3),

13-26.

[10] Saberi, S., Kouhizadeh, M., Sarkis, J., &

Shen, L. (2019). Blockchain technology and

its relationships to sustainable supply chain

management. International Journal of

Production Research, 57(7), 21-213.

[11] Jacob, C., Bourke, S., & Heuss, S. (2022).

From Testers to Cocreators—the Value of and

Approaches to Successful Patient Engagement

in the Development of eHealth Solutions:

Qualitative Expert Interview Study. JMIR

Human Factors, 9(4), 1-28.

[12] Debnath, S. (2023). Integrating Information

Technology in Healthcare: Recent

Developments, Challenges, and Future

Prospects for Urban and Regional Health.

arXiv preprint arXiv:2307, 11-29.

[13] Harvey, J. F. (2023). Microfoundations of

sensing capabilities: From managerial

cognition to team behavior. Strategic

Organization, 13-269.

[14] Murphy, W. H., & Wilson, G. A. (2022).

Dynamic capabilities and stakeholder theory

explanation of superior performance among

award-winning hospitals. International

Journal of Healthcare Management, 15(3),

211-219.

[15] Shruthi, K., & Poornima, A. S. (2023).

Medical Data Asset Management and an

Approach for Disease Prediction using

Blockchain and Machine Learning.

International Journal of Engineering Trends

and Technology, 1-28.

[16] Massaro, M. (2021). Digital transformation in

the healthcare sector through blockchain

technology. Insights from academic research

and business developments. Technovation,

135-2678.

[17] Kang, J., Wen, J., Ye, D., Lai, B., Wu, T.,

Xiong, Z., Xie, S. (2023). Blockchain-

empowered Federated Learning for

Healthcare Metaverses: User-centric Incentive

Mechanism with Optimal Data Freshness.

IEEE Transactions on Cognitive

Communications and Networking, 13-26.

[18] Idrees, S. M., Agarwal, P., & Alam, M. A.

(Eds.). (2021). Blockchain for healthcare

systems: challenges, privacy, and securing of

data. CRC Press, 1-36.

[19] Torongo, A. A., & Toorani, M. (2023).

Blockchain-based Decentralized Identity

Management for Healthcare Systems. arXiv

preprint arXiv:2307, 13-239.

WSEAS TRANSACTIONS on INFORMATION SCIENCE and APPLICATIONS

DOI: 10.37394/23209.2024.21.24

Antonio Pesqueira, Maria José Sousa,

Andreia De Bem Machado

E-ISSN: 2224-3402

261

Volume 21, 2024

[20] Dillard-Wright, J., & Shields-Haas, V. (2021).

Nursing with the people: Reimagining futures

for nursing. Advances in Nursing Science,

44(3), 195-209.

[21] Nguyen, N. T., Tran, T. K., Tukayev, U.,

Hong, T. P., Trawiński, B., & Szczerbicki, E.

(Eds.). (2022). Intelligent Information and

Database Systems: 14th Asian Conference,

ACIIDS 2022, Ho Chi Minh City, Vietnam,

November 28–30, 2022, Proceedings, Part II

(Vol. 13758). Springer Nature, 1-26.

[22] Kwok, A. O., & Treiblmaier, H. (2023).

Blockchain technology as a driver of

economic development in small economies: a

dynamic capabilities framework. Journal of

Decision Systems, 1-26,

https://doi.org/10.1080/12460125.2023.22143

04.

[23] Ivanov, D. (2021). Lean resilience: AURA

(Active Usage of Resilience Assets)

framework for post-COVID-19 supply chain

management. The International Journal of

Logistics Management, 73-126.

[24] Nikolakis, W., John, L., & Krishnan, H.

(2018). How blockchain can shape sustainable

global value chains: an evidence, verifiability,

and enforceability (EVE) framework.

Sustainability, 10(11), 13-287.

[25] Meisami, S., Meisami, S., Yousefi, M., &

Aref, M. R. (2023). Combining Blockchain

and IOT for Decentralized Healthcare Data

Management. arXiv preprint

arXiv:2304.00127, 1-264.

[26] Rejeb, A., Rejeb, K., Simske, S., &

Treiblmaier, H. (2021). Blockchain

Technologies in Logistics and Supply Chain

Management: A Bibliometric Review.

Logistics, 5(4), 1-250.

[27] Kähkönen, A. K., Evangelista, P., Hallikas, J.,

Immonen, M., & Lintukangas, K. (2023).

COVID-19 as a trigger for dynamic capability

development and supply chain resilience

improvement. International Journal of

Production Research, 61(8), 2696-2715.

[28] Kumar, M., Raj, H., Chaurasia, N., & Gill, S.

S. (2023). Blockchain inspired secure and

reliable data exchange architecture for cyber-

physical healthcare system 4.0. Internet of

Things and Cyber-Physical Systems, 13-26.

[29] Pietronudo, M. C., Zhou, F., Caporuscio, A.,

La Ragione, G., & Risitano, M. (2022). New

emerging capabilities for managing data-

driven innovation in healthcare: the role of

digital platforms. European Journal of

Innovation Management, 25(6), 867-891.

[30] Tanniru, M. R., Woo, C., & Dutta, K. (2023).

A Conceptual Model to Share Resources and

Align Goals: Building Blockchain Application

to Support Care Continuity Outside a

Hospital. Journal of Risk and Financial

Management, 16(4), 10-256.

[31] Zekiye, A., & Özkasap, Ö. (2023).

Decentralized Healthcare Systems with

Federated Learning and Blockchain. arXiv

preprint arXiv:2306, 12-287.

[32] Kouba, P., Kohout, P., Haddadi, F., Bushuiev,

A., Samusevich, R., Sedlar, J., & Mazurenko,

S. (2023). Machine Learning-Guided Protein

Engineering. ACS catalysis, 13(21), 133-

1395.

[33] Katuwal, G. J., Pandey, S., Hennessey, M., &

Lamichhane, B. (2018). Applications of

blockchain in healthcare: current landscape

& challenges. arXiv preprint

arXiv:1812.02776, 12-24.

[34] Nguyen, A. M. (2023). Challenges of

Blockchain Applications in Digital Health: A

Systematic Review. arXiv preprint arXiv:2304,

11-29.

[35] Qu, Y., Ma, L., Ye, W., Zhai, X., Yu, S., Li,

Y., & Smith, D. (2023). Towards Blockchain-

Assisted Privacy-Aware Data Sharing For

Edge Intelligence: A Smart Healthcare

Perspective. arXiv preprint arXiv:2345, 10-

287.

[36] Ball, P. (2021). What the COVID-19

pandemic reveals about science, policy and

society. Interface Focus, 11(6), 1354-2678.

[37] Palaskas, A. (2022). Exploring Digital

Transformation in Public Healthcare: Drivers,

Success Factors, and Challenges, 13-125,

Master Thesis, International Hellenic

University.

[38] Cerchione, R., Centobelli, P., Riccio, E.,

Abbate, S., & Oropallo, E. (2023).

Blockchain’s coming to hospital to digitalize

healthcare services: Designing a distributed

electronic health record ecosystem.

Technovation, 120, 5-346.

WSEAS TRANSACTIONS on INFORMATION SCIENCE and APPLICATIONS

DOI: 10.37394/23209.2024.21.24

Antonio Pesqueira, Maria José Sousa,

Andreia De Bem Machado

E-ISSN: 2224-3402

262

Volume 21, 2024

Contribution of Individual Authors to the

Creation of a Scientific Article (Ghostwriting

Policy)

The authors equally contributed to the present

research, at all stages from the formulation of the

problem to the final findings and solution.

Sources of Funding for Research Presented

This research was not funded.

Conflict of Interest

The authors have no conflicts of interest to declare.

Creative Commons Attribution License 4.0

(Attribution 4.0 International, CC BY 4.0)

This article is published under the terms of the

Creative Commons Attribution License 4.0

https://creativecommons.org/licenses/by/4.0/deed.en

_US

WSEAS TRANSACTIONS on INFORMATION SCIENCE and APPLICATIONS

DOI: 10.37394/23209.2024.21.24

Antonio Pesqueira, Maria José Sousa,

Andreia De Bem Machado

E-ISSN: 2224-3402

263

Volume 21, 2024